Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myrcludex B - MYR Pharma

Drug Profile

Myrcludex B - MYR Pharma

Alternative Names: MyrB; Myrcludex-B

Latest Information Update: 07 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM; University of Heidelberg; Vision7
  • Developer Hepatera; MYR Pharma; Vision7
  • Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
  • Mechanism of Action Hepatitis B virus replication inhibitors; Sodium-bile acid cotransporter inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D
  • Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 09 Nov 2018 Interim adverse events data from the phase IIb MYR-203 trial for Hepatitis B and Hepatitis D presented at the 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
  • 23 Oct 2018 Myrcludex B receives Breakthrough Therapy status for Hepatitis D in USA
  • 23 Oct 2018 MYR Pharma plans a phase III trial for Hepatitis D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top